AKEBIA THERAPEUTICS, INC. Restricted Cash, Noncurrent
AKEBIA THERAPEUTICS, INC. (AKBA) had Restricted Cash, Noncurrent of $0 as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:RestrictedCashNoncurrent · last filed 2026-02-26
- 2025-12-31: Restricted Cash, Noncurrent $0.00.
- 2025-09-30: Restricted Cash, Noncurrent $0.00.
- 2025-06-30: Restricted Cash, Noncurrent $1.69M.
- 2025-03-31: Restricted Cash, Noncurrent $1.69M.
| Period end | Restricted Cash, Noncurrent |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-26 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-10 |
| 2025-06-30 | $1.69M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $1.69M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $1.68M 10-K · filed 2026-02-26 |
| 2024-09-30 | $1.67M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $1.67M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $1.66M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $1.65M 10-K · filed 2025-03-13 |
| 2022-12-31 | $2.70M 10-K · filed 2024-03-14 |
| 2021-12-31 | $2.04M 10-K/A · filed 2023-08-28 |
| 2020-12-31 | $2.04M 10-K/A · filed 2023-08-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |